Patara Pharma has announced Phase 2 results for its PA101 inhaled treatment for refractory chronic cough in patients with idiopathic pulmonary fibrosis (IPF) showing that patients receiving PA101 experienced a statistically significant reduction in cough frequency after 14 days compared to patients receiving a placebo. PA101 is delivered via the PARI eFlow nebulizer system.
The study, which included 24 patients, also showed improvement in patient reported quality of life related to cough and cough severity. PA101 was well tolerated and caused no significant adverse events, the company reported.
Patara Pharma Chief Medical Officer Ahmet Tutuncu commented, “Chronic cough is a debilitating symptom for many IPF patients that can contribute to poor quality of life, psycho-social complications and potentially more rapid disease progression. We are encouraged by the significant improvement in chronic cough we observed among patients in our positive Phase 2 trial, and we plan to move forward in early 2017 with a robust Phase 2b study to identify the optimal dose.”
Read the Patara Pharma press release.
